SAN DIEGO, March 15, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that David Moskowitz, Vice President
of Strategy and Corporate Communications, is scheduled to present a
corporate overview at the 27th Annual Oppenheimer
Healthcare Conference on Wednesday, March
22, 2017 at 3:55 p.m. Eastern
time (12:55 p.m. Pacific
time). The conference is being held at The Westin New
York Grand Central in New York
City.
A live webcast of the corporate presentation will be available
on the Company's website at ir.biocept.com. A replay of the
presentations will be available for 90 days.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands
of tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-27th-annual-oppenheimer-healthcare-conference-300422831.html
SOURCE Biocept, Inc.